Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells

Blood

Volumn 104, Issue 2, 2004, Pages 519-525

  Lunghi, Paolo ^c   Costanzo, Antonio ^c   Levrero, Massimo ^b   Bonati, Antonio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ARSENIC TRIOXIDE; PROTEIN P73; PROTEIN P73ALPHA; TYROSINE; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; BAX GENE; CANCER CELL; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DELTA NP73 GENE; ERYTHROLEUKEMIA CELL; GENE; GENE INACTIVATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; P21 GENE; P300 GENE; P53 REGULATED APOPTOSIS INDUCING PROTEIN 1 GENE; P73 GENE; PHOSPHOACETYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 3142590360     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2743     Document Type: Article

References (57)

1. Waxman S, Anderson K. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6(suppl 2):3-10.
2. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324.
3. Soignet SL, Frankel SR, Douer D, et al. United States multicenter trial of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
4. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.
5. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705-714.
6. Kurki S, Latonen L, Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci. 2003;116:3917-3925.
7. 3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med. 2001;193:1361-1371.
8. Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kB essentially ccntributes to arsenic-induced apoptosis. Blood. 2003;102;1028-1034.
9. Lin DY, Lai MZ, Ann DK, Shih HM. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J Biol Chem. 2003;278:15958-15965.
10. Verma A, Mohindru M, Deb DK, et al. Activation of Racl and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem. 2002;277:44988-44995.
11. Kaghad M, Bonnet H, Yang A, et al, Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-819.
12. Augustin M, Bamberger C, Paul D, et al. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm Genome. 1998;9:899-902.
13. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002;2:605-615.
14. Gong J, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806-809.
15. Agami R, Blandino G, Oren M, et al. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature. 1999;399:809-813.
16. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999;399:814-817.
17. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;418:580-564.
18. De Laurenzi V, Costanzo A, BarcaroIi D, et al. Two new p73 splice variants, γ an δ, with different transcriptional activity, J Exp Med. 1998;188:1763-1768.
19. Pozniak CD, Radinovic S, Yang A, et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000;289:304-306.
20. Grob TJ, Novak U, Maisse C et al. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213-1223.
21. Ishimoto O, Kawahara C, Enjo K, et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002;62:636-641.
22. Stiewe T, Zimmermann S, Frilling A, et al. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 2002;62:3598-3602.
23. Freebern WJ, Smith JL, Chaudhry SS, et al. Novel cell specific and dominant negative anti-apoptotic roles of p73 in transformed leukemia cells. J Biol Chem. 2003;278:2249-2255.
24. Vossio S, Palescandolo E, Pediconi N, et al. ΔNp73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene. 2002;21:3796-3803.
25. Kartasheva NN, Contente A, Lenz-Stoppler C, et al. p53 induces the expression of its antagonist p73 Delta N, establishing an autoregolatory feedback loop. Oncogene. 2002;21:4715-4727.
26. Zaika AI, Slade N, Erster SH, et al. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002;196:765-780.
27. Oda K, Arakawa H, Tanaka T et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102:849-862.
28. Costanzo A, Medo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell. 2002;9:175-186.
29. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387-402.
30. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
31. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995;270:27489-27494.
32. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810-816.
33. Lunghi P, Tabilio A, Dall'Aglio PP, et al. Down-modulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. 2003;17:1783-1793.
34. Milella M, Komblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108:851-859.
35. + fraction of chronic myelogenous leukemias. Cancer Res. 2000;60:728-732.
36. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98:49-56.
37. Milella M, Estrov Z, Komblau SM, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK-MAPK pathways in acute myelogenous leukemia. Blood. 2002;99:3461-3464.
38. Platanias LC. Map kinase signaling pathways and hematological malignancies. Blood. 2003;101:4667-4679.
39. Lee JT, McCubrey JA, The Raf/MEK/ERK (MAPK) signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 2002;16:486-507.
40. Song X, Sheppard HM, Norman AW, Liu X. Mitogen-activated protein kinase is involved in the degradation of p53 protein in bryostatin-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line. J Biol Chem. 1999;274:1677-1682.
41. Yih LH, Lee TC. Arsenite induces p53 accumulation through an ATM -dependent pathway in human fibroblasts. Cancer Res. 2000;60:6346-6352.
42. Dong, JT, Luo XM. Arsenic-induced DNA-strand breaks associated with DNA-protein crosslinks in human fetal lung fibroblasts. Mutat Res. 1993;302:97-102.
43. Lynn S, Shiung JN, Gurr JR, Jan KY. Arsenite stimulates poly(ADPribosylation) by generation of nitric oxide. Free Radicals Biol Med. 1998;24:442-449.
44. Schaumloffel N, Gebel, T. Heterogeneity of the DNA damage provoked by antimony and arsenic. Mutagenesis. 1998;13:281-286.
45. Mei N, Lee J, Sun X, et al. Genetic predisposition to the cytotoxicity of arsenic: the role of DNA damage and ATM. FASEB J. 2003;17:2310-2312.
46. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83:1179-1187.
47. 2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148-1158.
48. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000;95:1014-1022.
49. Nimmanapalli R, Bali P, O'Bryan E, Kuhn D, Bhalla K. Mechanism by which arsenic trioxide downregulates Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells [abstract]. Blood. 2001;98:618a.
50. D'Orazi G, Cecchinelli B, Bruno T et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002;4:11-19.
51. Kim EJ, Park JS, Um S. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. J Biol Chem. 2002;277:32020-32028.
52. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
53. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A. 2001;98:9742-9747.
54. Lipardi C, Wei Q and Paterson BM. RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell. 2001;107:297-307.
55. Nishikura K. A Short Primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell. 2001;107:415-418.
56. Sijen T, Fleenor J, Simmer F, et al. On the role of RNA amplification in dsRNA-triggered gene silencing. Cell. 2001;107:465-476.
57. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403-410.